Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 14/20 | 0.55 |
| ▸ | CDC7 | O00311 | 13/20 | 0.55 |
| ▸ | DBF4 | Q9UBU7 | 13/20 | 0.55 |
| ▸ | CCNE1 | P24864 | 12/20 | 0.55 |
| ▸ | CDK2 | P24941 | 12/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL614116 | 0.82 | CDC7 (0.58) | ROCK1CDC7DBF4CCNE1CDK2 | |
| SCHEMBL612601 | 0.72 | CDC7 (0.72) | ROCK1CDC7DBF4CCNE1CDK2 | |
| SCHEMBL613530 | 0.71 | CDC7 (1.00) | ROCK1CDC7DBF4CCNE1CDK2 | |
| SCHEMBL12917990 | 0.70 | SDHB (0.35) | — | |
| SCHEMBL2986306 | 0.68 | IKBKB (0.48) | CDC7 | |
| SCHEMBL2198259 | 0.67 | KDM4E (0.38) | — | |
| SCHEMBL612624 | 0.66 | CDC7 (0.69) | ROCK1CDC7DBF4CCNE1CDK2 | |
| SCHEMBL3568782 | 0.66 | CDK2 (0.59) | CCNE1CDK2 | |
| SCHEMBL7421078 | 0.65 | GABRA1 (0.39) | — | |
| SCHEMBL613712 | 0.64 | CDC7 (0.64) | ROCK1CDC7DBF4CCNE1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2403857-B1 | THIENOPYRIMIDINE AS CDC7 KINASE INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2013-12-04 | — | — | EP | disclosed |
| US-20120040981-A1 | THIENOPYRIMIDINE AS CDC7 KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040981-A1 | THIENOPYRIMIDINE AS CDC7 KINASE INHIBITORS | CDC7, CDK7, DTYMK | ROCK1 2609/4885CDC7 1/4885DBF4 593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.